Association between omentin-1, adiponectin and bone health under consideration of osteoprotegerin as possible mediator.
OBJECTIVE
Several studies implicated a crosstalk between bone and fat in the pathogenesis of osteoporosis. Few studies indicated an association between adiponectin and omentin-1 on the bone remodeling process and bone mineral density, and suggested osteoprotegerin (OPG) as a mediator of this relationship. However, only limited evidence on this relationship is available in humans. Therefore, this study aimed to investigate the association between omentin-1, adiponectin and broadband ultrasound attenuation (BUA) in peri-/premenopausal and postmenopausal women, and to assess the role of OPG as a possible mediator.


METHODS
Data from the German population-based EPIC-Potsdam cohort comprising 637 women were analyzed. Multivariable-adjusted ANCOVA including age, BMI, waist circumference, smoking status, education, physical activity, adiponectin or omentin-1 and hormone use was used to investigate potential relationships between the adipokines and BUA levels. A mediation analysis assessed the mediating effect of OPG on the association of BUA and omentin-1 levels.


RESULTS
Peri-/premenopausal women had higher BUA levels (112.5 ± 10.1 dB/MHz), compared to postmenopausal women (106.3 ± 10.0 dB/MHz). In peri-/premenopausal women neither adiponectin nor omentin-1 was significantly associated with BUA. In postmenopausal women, adiponectin was not associated with BUA, but 10 % increase in the omentin-1 concentration was significantly associated with 0.44 dB/MHz lower BUA levels (p = 0.01). Omentin-1 was positively associated with OPG (p = 0.02); however, OPG was not significantly related to BUA (p = 0.62).


CONCLUSIONS
Our study provides evidence for an inverse association between circulating omentin-1 and BUA levels in postmenopausal women. However, the present findings do not support a mediating effect of OPG in the adipose tissue-bone pathway.
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany. Juliane.Menzel@dife.de.|Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany. Juliane.Menzel@dife.de.|German Center for Diabetes Research (DZD), München-Neuherberg, Germany. Juliane.Menzel@dife.de.
J
J
Menzel
Institute of Epidemiology, Christian-Albrechts University Kiel, Kiel, Germany.
R
R
Di Giuseppe
Institute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
R
R
Biemann
Nutrition, Immunity and Metabolism Start-up Lab, Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.|Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
K
K
Aleksandrova
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany.
O
O
Kuxhaus
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany.|German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
C
C
Wittenbecher
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.|Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, Department of Internal Medicine, University of Tübingen, Tübingen, Germany.
A
A
Fritsche
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany.|German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
M B
MB
Schulze
Institute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
B
B
Isermann
Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
H
H
Boeing
Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany.|Department of Food Safety, Federal Institute for Risk Assessment, Berlin, Germany.
C
C
Weikert
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D015415:Biomarkers / Q000032:analysis*; D015519:Bone Density; D016207:Cytokines / Q000097:blood*; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood; D006801:Humans; D037102:Lectins / Q000097:blood*; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000175:diagnosis*; D053244:Osteoprotegerin / Q000097:blood*; D017698:Postmenopause; D017697:Premenopause; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D014463:Ultrasonography / Q000379:methods*
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D037102:Lectins; D053244:Osteoprotegerin
Bone mineral density; Broadband ultrasound attenuation; Intelectin-1; Osteoclastogenesis inhibitory factor